Table 2.
Biomarker results by subgroup
| Biomarker | All cases | All ER-positive | ER-positive tamoxifen only a | ER-positive, node-negative, tamoxifen only a |
|---|---|---|---|---|
| SLC7A5 | ||||
| 0 | 1231 (79.9%) | 1035 (87.0%) | 732 (88.1%) | 578 (88.0%) |
| 1 | 139 (9.0%) | 77 (6.5%) | 51 (6.1%) | 38 (5.8%) |
| 2 | 41 (2.7%) | 24 (2.0%) | 11 (1.3%) | 9 (1.4%) |
| Missingb | 129 (8.4%) | 53 (4.5%) | 37 (4.5%) | 32 (4.9%) |
| HTF9C | ||||
| 0 | 1234 (80.1%) | 1015 (85.4%) | 712 (85.7%) | 559 (85.1%) |
| 1 | 103 (6.7%) | 69 (5.8%) | 43 (5.2%) | 35 (5.3%) |
| 2 | 72 (4.7%) | 46 (3.9%) | 36 (4.3%) | 25 (3.8%) |
| Missing | 131 (8.5%) | 59 (5.0%) | 40 (4.8%) | 38 (5.8%) |
| NDRG1 | ||||
| 0 | 1085 (70.5%) | 904 (76.0%) | 624 (75.1%) | 495 (75.3%) |
| 1 | 175 (11.4%) | 127 (10.7%) | 96 (11.6%) | 75 (11.4%) |
| 2 | 148 (9.6%) | 100 (8.4%) | 66 (7.9%) | 47 (7.2%) |
| Missing | 132 (8.6%) | 58 (4.9%) | 45 (5.4%) | 40 (6.1%) |
| CEACAM5 | ||||
| 0 | 1251 (81.2%) | 1005 (84.5%) | 699 (84.1%) | 550 (83.7%) |
| 1 | 75 (4.9%) | 67 (5.6%) | 46 (5.5%) | 39 (5.9%) |
| 2 | 77 (5.0%) | 61 (5.1%) | 44 (5.1%) | 29 (4.4%) |
| Missing | 137 (8.9%) | 56 (4.7%) | 44 (5.3%) | 39 (5.9%) |
| P53 | ||||
| 0 | 1040 (67.5%) | 884 (74.3%) | 619 (74.5%) | 479 (72.9%) |
| 1 | 229 (14.9%) | 166 (14.0%) | 119 (14.3%) | 101 (15.4%) |
| 2 | 117 (7.6%) | 67 (5.6%) | 39 (4.7%) | 30 (4.6%) |
| Missing | 154 (10.0%) | 72 (6.1%) | 54 (6.5%) | 47 (7.2%) |
| LMH | ||||
| Low | 717 (46.6%) | 643 (54.1%) | 444 (53.4%) | 341 (51.9%) |
| Medium | 305 (19.8%) | 244 (20.5%) | 175 (21.1%) | 139 (21.2%) |
| High | 278 (18.1%) | 168 (14.1%) | 112 (13.5%) | 88 (13.4%) |
| Missing | 240 (15.6%) | 134 (11.3%) | 100 (12.0%) | 89 (13.5%) |
| Total | 1300 | 1055 | 731 | 568 |
ER, estrogen receptor; LMH, low, medium, or high. aTamoxifen only, patients treated with adjuvant tamoxifen without adjuvant chemotherapy. bMissing data due to loss of cores from tumor microarrays or no tumor in the tumor microarray core.